http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#Head
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#assertion
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#provenance
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#pubinfo
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#assertion
http://purl.obolibrary.org/obo/DOID_14320
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_14320
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01175
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association
http://www.w3.org/2000/01/rdf-schema#label
escitalopram oxalate is a selective serotonin reuptake inhibitor ssri indicated for acute and maintenance treatment of major depressive disorder mdd in adults and adolescents aged 12 17 years 1 1 acute treatment of generalized anxiety disorder gad in adults 1 2 acute treatment of generalized anxiety disorder gad in adults 1 2 escitalopram tablets usp are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age see clinical studies 14 1 a major depressive episode dsm iv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least five of the following nine symptoms depressed mood loss of interest in usual activities significant change in weight and or appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration a suicide attempt or suicidal ideation escitalopram tablets usp are indicated for the acute treatment of generalized anxiety disorder gad in adults see clinical studies 14 2 generalized anxiety disorder dsm iv is characterized by excessive anxiety and worry apprehensive expectation that is persistent for at least 6 months and which the person finds difficult to control it must be associated with at least 3 of the following symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension and sleep disturbance
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01175
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#provenance
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#pubinfo
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#sig
http://purl.org/nanopub/x/hasSignature
PuCBfcb/k8hRBzRl59Z3br3bINbcQfvlh41b6woxKM8wl+2h1Tz7Dj4bbSkbg7Xdu7o0XbxbFENdgYBNFPKtdDOkJQ+lmurx3FRTn/8N9YxEIXn1aMy+btuuyyL4ti9EycYOEhA0WSgVB35KX+Pvxxvhpy7K6CsX1GB1IaDZUFM=
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
http://purl.org/dc/terms/created
2021-06-13T14:10:53.808+02:00
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs